Literature DB >> 11434472

Why do patients with rheumatoid arthritis use alternative treatments?

F W Kraaimaat, J W Bijlsma.   

Abstract

The aim of this study was to analyse the characteristics of patients with rheumatoid arthritis (RA) who make use of alternative or complementary medicine (CM). Two hundred and sixty-two randomly chosen patients with RA filled out self-assessment health status and pain questionnaires. Differences between the group of patients making use of both CM and conventional treatment (n = 52) and the group of patients who relied only on conventional treatment prescribed by their rheumatologists (n = 210) were explored with respect to demographic characteristics, duration of RA, levels of physical, psychological and social functioning, and pain-coping behaviour. We found that female patients used CM more often than did male patients, and those who used CM were younger than those who did not. There were no differences with respect to duration of RA, physical, psychological or social functioning or pain coping; however, the perceived impact of RA on several domains of life was higher in patients who used CM than in those who did not. Nevertheless, the patient groups did not differ in terms of medical consumption, except that those who used CM visited medical specialists for RA-related complaints less than those who relied only on conventional treatments. We concluded that the higher impact of RA, in the absence of worse disease, perceived by users of CM in several domains of life, especially psychosocial functioning, could be the reason they use CM. This suggests that CM cannot be substituted by additional conventional treatment prescribed by the rheumatologist, but rather by psychosocial intervention.

Entities:  

Mesh:

Year:  2001        PMID: 11434472     DOI: 10.1007/pl00011199

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  7 in total

1.  [Out-of-pocket medical spending for care in patients with recent onset rheumatoid arthritis].

Authors:  G Westhoff; J Listing; A Zink
Journal:  Z Rheumatol       Date:  2004-10       Impact factor: 1.372

2.  Use of complementary medicines for osteoarthritis--a prospective study.

Authors:  J Zochling; L March; H Lapsley; M Cross; K Tribe; P Brooks
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

3.  Complementary and alternative medicine use in African Americans with rheumatoid arthritis.

Authors:  Ashutosh Tamhane; Gerald McGwin; David T Redden; Laura B Hughes; Elizabeth E Brown; Andrew O Westfall; Doyt L Conn; Beth L Jonas; Edwin A Smith; Richard D Brasington; Larry W Moreland; S Louis Bridges; Leigh F Callahan
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-02       Impact factor: 4.794

4.  Anti-arthritic effects of magnolol in human interleukin 1β-stimulated fibroblast-like synoviocytes and in a rat arthritis model.

Authors:  Jyh-Horng Wang; Kao-Shang Shih; Jing-Ping Liou; Yi-Wen Wu; Anita Shin-Yuan Chang; Kang-Li Wang; Ching-Lin Tsai; Chia-Ron Yang
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

Review 5.  Molecular Targets of Natural Products for Chondroprotection in Destructive Joint Diseases.

Authors:  Thanasekaran Jayakumar; Periyakali Saravana Bhavan; Joen-Rong Sheu
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

6.  Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1beta-stimulated fibroblast-like synoviocytes and in rat arthritis models.

Authors:  Jun Soo Bang; Da Hee Oh; Hyun Mi Choi; Bong-Jun Sur; Sung-Jig Lim; Jung Yeon Kim; Hyung-In Yang; Myung Chul Yoo; Dae-Hyun Hahm; Kyoung Soo Kim
Journal:  Arthritis Res Ther       Date:  2009-03-30       Impact factor: 5.156

7.  Prevalence of and factors associated with utilization of herbal medicines among outpatients in primary health centers in Cambodia.

Authors:  Hattie Pearson; Tyler Fleming; Pheak Chhoun; Sovannary Tuot; Carinne Brody; Siyan Yi
Journal:  BMC Complement Altern Med       Date:  2018-04-02       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.